Dermatology

Prof Girolomoni provided an overview of psoriasis, considering how patients are frequently affected by other comorbidities.

The oral session consisted of a talk on the 2-year efficacy and safety of guselkumab in the treatment of moderate-to-severe psoriasis from the Phase III VOYAGE 1 trial.

Prof Costanzo welcomed attendees to the symposium and outlined the agenda before explaining the autoimmune pathophysiology that underlies psoriasis.

This symposium is focused on topical therapies in the treatment of psoriasis and the unmet clinical and patient quality of life needs.

Dermatologists today have more tools than ever at their disposal for managing psoriasis, including newer-generation biologics, which target molecular…

La EVC es una enfermedad preocupante que genera una carga significativa sobre los servicios sanitarios y la sociedad en general.

CVD is a very concerning condition which creates a significant burden on healthcare provision and wider society. Varicose veins are often the first sign of CVD.

The main objectives of this symposium were to explore the effect of light on individuals with hyperpigmentation disorders and acne, present the latest…